Please assess the completion status of the following clinical trial:

Trial Title: De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients at 15-65 years of age undergoing renal transplantation~* Patients who have been informed of the potential risks and side effects of the study~* Patients who have given written informed consent to participate in the study~* Females who are not pregnant or nursing women (pregnancy test required)~Exclusion Criteria:~* Donor age greater than 65 years~* Patients receiving a perfectly matched kidney (6 matches HLA A, B, DR)~* Patients who are recipients of multiple solid organ transplants~* Patients undergoing second or subsequent transplantation~* Patients with pre-transplant PRA \> 30%~* Patients with ABO incompatibility or positive lymphocytotoxicity~* Patients with severe, active infection~* Patients who have an abnormal liver profile such as ALT, AST, alkaline phosphatase or total bilirubin \>3 times the upper normal limit~* Patient who are HIV-positive or hepatitis C (PCR+ only) B surface antigen positive~* Patients who have been treated with an investigational drug or therapy within one month prior to entry or who will be so treated within 6 months of transplantation~* Patients with a history of malignancy within the last five years except excised squamous or basal cell carcinoma~* Patients with a history of alcohol or drug abuse or signs of alcohol-induced organ damage, mental dysfunction or other factors limiting their ability to comply fully with the study requirements.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- rituximab and everolimus (Type: ACTIVE_COMPARATOR): Patients of the study arm will receive rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus will be given with an initial dose of 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
- thymoglobulin and tacrolimus (Type: ACTIVE_COMPARATOR): The control arm will receive thymoglobulin induction and tacrolimus-based immunosuppressive therapy. The dose of thymoglobulin would be 1.0mg/kg/d for 3 days25. The first dose of thymoglobulin will be administered before graft kidney reperfusion, and so is rituximab. All patients will receive corticosteroid therapy as usual. The initial daily dose of tacrolimus will be 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation. The doses of tacrolimus will be adjusted to target the whole blood trough levels between 8 to 12 ng/ml during the first 30 days after transplantation, and tapered to 6 to 10 ng/ml at 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).